Celularity Inc
For the period ended Mar 31, 2024. Filed Oct 16, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Oct 16, 2024
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statements of Stoc kholders’ Equity (Unaudited)
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-in · Accumulated · Accumulated Other Comprehensive · TotalStockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Deficit · Income (Loss) · Equity | ||||||||
| Balances at January 1, 2024 | 19,378,192 | $2 | $882,749 | $(841,791) | $ | - | $40,960 | |
| Issuance of common stock to Yorkville for debt extension and SEPA commitment fee | 116,964 | - | 317 | - | - | 317 | ||
| Issuance and modification of warrants to RWI and C.V. Starr | - | - | 3,322 | - | - | 3,322 | ||
| Issuance of common stock and warrants in PIPE Offering, net of offering expenses | 2,141,098 | - | 6,000 | - | 6,000 | |||
| Vesting of restricted stock units | 233,361 | - | - | - | - | |||
| Tax withholding on vesting of restricted stock units | (80,672) | - | (357) | - | - | (357) | ||
| Issuance of common stock to Palantir as consideration for settlement agreement | 20,000 | - | 50 | - | - | 50 | ||
| Retirement of shares in connection with reverse stock split | (191) | - | - | - | - | - | ||
| Stock-based compensation expense | - | - | 2,966 | - | - | 2,966 | ||
| Net loss | - | - | - | (22,013) | - | (22,013) | ||
| Balances at March 31, 2024 | 21,808,752 | $2 | $895,047 | $(863,804) | $ | - | $31,245 | |
| Balances at January 1, 2023 | 14,892,129 | $1 | $844,387 | $(645,496) | $9 | $198,901 | ||
| Exercise of stock options | 107,100 | - | 300 | - | - | 300 | ||
| Common stock issued pursuant to short-term debt conversion | 365,612 | - | 3,510 | - | (152) | 3,358 | ||
| Issuance of common stock in PIPE Offering, net of offering expenses | 938,183 | - | 8,931 | - | - | 8,931 | ||
| Issuance of common stock for stem-cells to be used in research and development | 169,492 | - | 1,000 | - | - | 1,000 | ||
| Vesting of restricted stock units | 25,339 | - | - | - | - | - | ||
| Tax withholding on vesting of restricted stock units | (8,110) | - | (53) | - | - | (53) | ||
| Issuance of common stock under ATM Agreement | 13,296 | - | 136 | - | - | 136 | ||
| Issuance of warrants on senior secured bridge loan | - | - | 274 | - | - | 274 | ||
| Stock-based compensation expense | - | - | 3,988 | - | - | 3,988 | ||
| Change in fair value of debt due to change in credit risk, net of tax | - | - | - | - | 2,810 | 2,810 | ||
| Net loss | - | - | - | (64,017) | - | (64,017) | ||
| Balances at March 31, 2023 | 16,503,041 | $1 | $862,473 | $(709,513) | $2,667 | $155,628 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.